

Fig. 3. Oligomeric Aip2p/Dld2p displays broad substrate specificity in vitro. (A) Heavy meromyosin (HMM) is unfolded by oligomeric Aip2p/Dld2p. One hundred microgram per milliliter of HMM was incubated with or without oligomeric Aip2p/Dld2p ( $100 \mu\text{g ml}^{-1}$ ) in buffer A containing 1 mM ATP as described in Materials and methods. Following incubation, each mixture was subjected to low angle shadowing electron microscopy. Scale bar is 50 nm. Right panel represents the increased trypsin susceptibility of oligomeric Aip2p/Dld2p-treated HMM (100 and 500 ng). HMM was immunostained with anti-HMM polyclonal antibody. (B) Trypsin susceptibility of oligomeric Aip2p/Dld2p-treated pathogenic highly aggregated proteins is dramatically increased. Recombinant prion protein (PrP) in  $\beta$ -sheet form (20  $\mu\text{g}$ ),  $\alpha$ -synuclein (20  $\mu\text{g}$ ), and amyloid  $\beta$  (1–42) peptide (60  $\mu\text{g}$ ) were used as specimens for negative staining (left panels). PrP in  $\beta$ -sheet form (300 ng),  $\alpha$ -synuclein (200 ng) and amyloid  $\beta$  (1–42) peptide (400 ng) were used for the trypsin susceptibility assay (right panels). PrP and  $\alpha$ -synuclein were immunostained with anti-PrP polyclonal antibody K1 (1:200) and anti- $\alpha$ -synuclein antibody, respectively. Amyloid  $\beta$  (1–42) peptide was silver stained according to the manufacturer's instruction (Wako Chemicals). Scale bars are 100 nm.

vitro. Both the substrate-binding and protein conformation modifying activities are regulated by the binding of ATP to Aip2p/Dld2p, but not by ATP hydrolysis.

This represents a distinct profile as reflected in known Group I and II chaperonins, which do not target the properly folded proteins [14–17]. In terms of the recognition of native (properly folded) proteins, the folding of native tubulin involves at least seven different chaperone proteins [18], while the structure of the yeast homolog of cofactor A, Rbl2p, is a dimer with largely hydrophilic surfaces, reflecting the fact that it interacts with quasi-native, and not unfolded,  $\beta$ -tubulin. In turn, these chaperone proteins do not recognize misfolded proteins. It is worth noting that the robust protein con-




Fig. 4. Aip2p/Dld2p modifies the conformation of F-actin in vivo in a cell cycle-dependent manner. Analysis of protein conformation modifying activity of Aip2p/Dld2p in stationary and log phase yeast cells. Synchronized yeast cells constitutively expressing C-terminally hexahistidine-tagged Aip2p/Dld2p were grown to  $\text{OD}_{600}$  of 0.5 (log phase, lane 2) or 11 (stationary phase, lane 3) and oligomeric Aip2p/Dld2p was purified from 10 mg each of total yeast cells according to the procedure described in Materials and methods. Protected actin band was detected according to the procedure of trypsin susceptibility assay. A thousandth of purified Aip2p/Dld2p at log or stationary phases was detected by Western blot analysis with anti-Aip2p/Dld2p antibody.

formation modifying activity of oligomeric Aip2p/Dld2p modulated the conformation of several pathogenic, highly aggregated proteins such as PrP in  $\beta$ -sheet form associated with prion disease [19],  $\alpha$ -synuclein associated with Parkinson's disease [20], and amyloid  $\beta$  (1–42) peptide associated with Alzheimer's disease [21].

As an example of the three-dimensional image of proteins with increased trypsin susceptibility, we directly visualized the “unfolded” structure of substrate protein (HMM) by oligomeric Aip2p/Dld2p with the low angle rotary shadowing electron microscopy. Based on our previous notion that the oligomeric Aip2p/Dld2p exhibits a grapple-like structure of 10–12 subunits with an ATP-dependent opening [4], we are tempted to speculate that substrate proteins probably enter the cavity of oligomeric Aip2p/Dld2p, where they were unfolded in the presence of ATP. Thus, protein unfolding seems to contribute, at least in part, to the aberrant trypsin susceptibility by oligomeric Aip2p/Dld2p.

When the oligomeric Aip2p/Dld2p regulates some protein metabolism in vivo through its unique protein conformation modifying activity, the activity as it is can be extremely dangerous for cells, as it exhibits broad substrate specificity in vitro. Thus, this activity has to be tightly controlled under very stringent regulation such as by other co-factor/s in vivo. In fact, partially purified Aip2p/Dld2p at the log phase possessed higher protein conformation modifying activity and ATP-binding capacity than that of Aip2p/Dld2p purified at the sta-

tionary phase, suggesting the presence of cofactor/s that may provide ATP to oligomeric Aip2p/Dld2p in yeast cells, where F-actin is supposed to be a major target in vivo [5].

Finally, these data further support our previous notion that the oligomeric Aip2p/Dld2p may belong to an unusual class of molecular chaperones [4]. The oligomeric Aip2p/Dld2p represents a unique grapple-like structure in an ATP-dependent opening, and is able to recognize both properly folded and highly aggregated proteins with broad substrate specificity in vitro. Whether these data represent a new regulatory mechanism of protein conformations in vivo has yet to be determined.

### Acknowledgments

We are indebted to G. Schatz, S.B. Prusiner, K. Mihara, and R. Scheckman for critical discussions and to I. Wada, N. Hoogenraad, M. Ryan, and A. Asano for helpful comments. We are also grateful to Y. Kozuka, K. Ihara, S. Yoshioka, M. Yamada, K. Watanabe, E.A. Nanri, and K. Ishibashi for technical assistance. This work was supported in part by grants from Exploratory Research for Advanced Technology (ERATO) and Core Research for Evolutional Science and Technology (CREST) of the Japan Science Technology Corporation (JST), Health and Labour Sciences Research Grants, Research on Advanced Medical Technology, nano-001, the Ministry of Health, Labour and Welfare of Japan, and the Naito Foundation.


### References

- [1] D.C. Amberg, E. Basart, D. Botstein, Defining protein interactions with yeast actin in vivo, *Nat. Struct. Biol.* 2 (1995) 28–35.
- [2] A. Chelstowska, Z. Liu, Y. Jia, D. Amberg, R.A. Butow, Signalling between mitochondria and the nucleus regulates the expression of a new D-lactate dehydrogenase activity in yeast, *Yeast* 15 (1999) 1377–1391.
- [3] M.J. Flick, S.F. Konieczny, Identification of putative mammalian D-lactate dehydrogenase enzymes, *Biochem. Biophys. Res. Commun.* 295 (2002) 910–916.
- [4] N.S. Hachiya, Y. Sakasegawa, S.H.A. Jozuka, S. Tsukita, K. Kaneko, Oligomeric Aip2p/Dld2p forms a novel grapple-like structure and has an ATP-dependent F-actin conformation modifying activity in vitro, *Biochem. Biophys. Res. Commun.* 320 (2004) 1271–1276.
- [5] N.S. Hachiya, Y. Sakasegawa, A. Jozuka, S. Tsukita, K. Kaneko, Interaction of D-lactate dehydrogenase protein 2 (Dld2p) with F-actin: implication for an alternative function of Dld2p, *Biochem. Biophys. Res. Commun.* 319 (2004) 78–82.
- [6] T.D. Pollard, The cytoskeleton, cellular motility and the reductionist agenda, *Nature* 422 (2003) 741–745.
- [7] N.S. Hachiya, K. Watanabe, Y. Sakasegawa, K. Kaneko, Microtubules-associated intracellular localization of the NH(2)-terminal cellular prion protein fragment, *Biochem. Biophys. Res. Commun.* 313 (2004) 818–823.
- [8] N.S. Hachiya, K. Watanabe, M. Yamada, Y. Sakasegawa, K. Kaneko, Anterograde and retrograde intracellular trafficking of fluorescent cellular prion protein, *Biochem. Biophys. Res. Commun.* 315 (2004) 802–807.
- [9] N. Hachiya, R. Alam, Y. Sakasegawa, M. Sakaguchi, K. Mihara, T. Omura, A mitochondrial import factor purified from rat liver cytosol is an ATP-dependent conformational modulator for precursor proteins, *EMBO J.* 12 (1993) 1579–1586.
- [10] N. Hachiya, T. Komiya, R. Alam, J. Iwahashi, M. Sakaguchi, T. Omura, K. Mihara, MSF, a novel cytoplasmic chaperone which functions in precursor targeting to mitochondria, *EMBO J.* 13 (1994) 5146–5154.
- [11] N. Hachiya, K. Mihara, K. Suda, M. Horst, G. Schatz, T. Lithgow, Reconstitution of the initial steps of mitochondrial protein import, *Nature* 376 (1995) 705–709.
- [12] E. Nimmesgern, F.U. Hartl, ATP-dependent protein refolding activity in reticulocyte lysate. Evidence for the participation of different chaperone components, *FEBS Lett.* 331 (1993) 25–30.
- [13] S. Tsukita, Desmocalmin: a calmodulin-binding high molecular weight protein isolated from desmosomes, *J. Cell Biol.* 101 (1985) 2070–2080.
- [14] T. Laufen, M.P. Mayer, C. Beisel, D. Klostermeier, A. Mogk, J. Reinstein, B. Bukau, Mechanism of regulation of hsp70 chaperones by DnaJ cochaperones, *Proc. Natl. Acad. Sci. USA* 96 (1999) 5452–5457.
- [15] R. Russell, A. Wali Karzai, A.F. Mehl, R. McMacken, DnaJ dramatically stimulates ATP hydrolysis by DnaK: insight into targeting of Hsp70 proteins to polypeptide substrates, *Biochemistry* 38 (1999) 4165–4176.
- [16] Y. Groemping, D. Klostermeier, C. Herrmann, T. Veit, R. Scidel, J. Reinstein, Regulation of ATPase and chaperone cycle of DnaK from *Thermus thermophilus* by the nucleotide exchange factor GrpE, *J. Mol. Biol.* 305 (2001) 1173–1183.
- [17] J.P. Grimshaw, I. Jelesarov, H.J. Schonfeld, P. Christen, Reversible thermal transition in GrpE, the nucleotide exchange factor of the DnaK heat-shock system, *J. Biol. Chem.* 276 (2001) 6098–6104.
- [18] J. Martin, Group II chaperonins as mediators of cytosolic protein folding, *Curr. Protein Pept. Sci.* 1 (2000) 309–324.
- [19] M.P. Mayer, H. Schroder, S. Rudiger, K. Paal, T. Laufen, B. Bukau, Multistep mechanism of substrate-binding determines chaperone activity of Hsp70, *Nat. Struct. Biol.* 7 (2000) 586–593.
- [20] J.T. Greenamyre, T.G. Hastings, Biomedicine. Parkinson's-divergent causes, convergent mechanisms, *Science* 304 (2004) 1120–1122.
- [21] J.W. Lustbader, M. Cirilli, C. Lin, H.W. Xu, K. Takuma, N. Wang, C. Caspersen, X. Chen, S. Pollak, M. Chaney, F. Trinchese, S. Liu, F. Gunn-Moore, L.F. Lue, D.G. Walker, P. Kuppasamy, Z.L. Zewier, O. Arancio, D. Stern, S.S. Yan, H. Wu, ABAD directly links a beta to mitochondrial toxicity in Alzheimer's disease, *Science* 304 (2004) 448–452.

### Cardiovascular Regeneration Therapies Using Tissue Engineering Approaches

The fact that the cardiovascular system transports oxygen and nutrients to all parts of the body makes any threat to its well-being a serious hazard to organs, tissues, and cells. This fundamental truth underlines the importance of research into cardiovascular regeneration and, therefore, of this collection outlining the latest developments in the field. With input from many of the leading researchers and practitioners, this book describes techniques for therapeutic angiogenesis and vasculogenesis for the treatment of ischemic diseases and examines the current approaches to angiogenic cytokines, cardiovascular stem cells, and tissue-engineering tools. The latest clinical results using bone marrow-derived mononuclear cell therapy for intractable circulatory disorders are also covered. This body of work will be a valuable resource for professionals in the fields of cardiovascular surgery, regenerative medicine, and tissue engineering.

ISBN 4-431-23924-3



springeronline.com

H. Mori  
H. Matsuda (Eds.)



Cardiovascular Regeneration Therapies  
Using Tissue Engineering Approaches

H. Mori • H. Matsuda (Eds.)

## Cardiovascular Regeneration Therapies Using Tissue Engineering Approaches

 Springer

## Contents

Preface.....	V
--------------	---

### Chapter 1: VASCULAR PRECURSOR CELLS AND THEIR POTENTIATION

EPC and Their Potentiation by Adenovirus Gene Delivery Iwaguro H and Asahara T.....	3
Potentiation of Regenerative Therapy by Non-Viral Vector, Gelatin Hydrogel Nagaya N, Fukuyama N, Tabata Y, Mori H.....	17
Regeneration of Myocardium Using Bone Marrow Cells Tomita S and Nakatani T.....	31

### Chapter 2: DEVELOPMENT OF MYOCARDIAL SHEETS AND THEIR CELL SOURCES

Cell Sheet Technology for Myocardial Tissue Engineering Shimizu T, Sekine H, Isoi Y, Yamato M, Kikuchi A, Okano T.....	45
Myocardial Regeneration Therapy with Tissue Implantation of Autologous Myoblast Sheets for Severe Impaired Heart Failure Sawa Y, Memori I, and Matsuda H.....	53
Cardiovascular Cell Differentiation from ES Cells Yamashita J.....	67

### Chapter 3: HYBRID TISSUES

Preparation and Recellularization of Tissue-Engineered Bioscaffold for Heart Valve Replacement Fujisato T, Minatoya K, Yamazaki S, Meng Y, Niwaya K, Kishida A, Nakatani T, Kitamura S.....	83
--	----

Biotube Technology for a Novel Tissue-Engineered Blood Vessels Ishibashi-Ueda H and Nakayama Y .....	95
Clinical Application of Tissue-Engineered Blood Vessels Matsumura G and Shin'oka T .....	105

**Chapter 4: NEW ASPECTS OF ANGIOGENESIS**

Vascular Regeneration and Remodeling by Circulating Progenitor Cells Sata M and Nagai R .....	117
Gene Therapy with Hepatocyte Growth Factor for Angiogenesis in Severe Pulmonary Vascular Disease Ono M, Sawa Y, and Matsuda H .....	129
Basic Fibroblast Growth Factor and Angiogenesis Marui A, Doi K, Tambara K, Sakakibara Y, Ueyama K, Iwakura A, Yanamoto M, Ikeda T, Tabata Y, Komeda M .....	145
Gene Therapy for Angiogenesis under a Ventricular Assist System Takewa Y, Shirakawa Y, Taenaka Y, Tatsumi E, Sawa Y, Matsuda H, Kitamura S, Takano H .....	157
The Role of Vascular Endothelial Growth Factor (VEGF) on Therapeutic Angiogenesis Using Bone Marrow Cells Maeda Y and Ikeda U .....	173

**Chapter 5: CLINICAL RESULTS OF THERAPEUTIC ANGIOGENESIS AND VASCULOGENESIS**

Clinical Survey of Cell Therapy in Japan Katsuda Y, Takeshita Y, Arima K, Saitoh Y, Imaizumi T, Asahara T, Nakatani T, Okano T, Kishida A, Ueda H, Shin'oka T, Nagai R, Sawa Y, Komeda M, Takewa Y, Matsuda H, Mori H .....	183
---	-----

IX Contents

---

A Novel Micro-Angiography Detecting Angiogenesis, Application for Autologous Bone Marrow Mononuclear Cells Transplantation in the Patients with Critical Limb Ischemia Nishigami K, Nakatani T, Chiku M, Mori H.....	191
Angiogenesis Induced by Intramyocardial Implantation of Autologous Bone Marrow Mononuclear Cells for the Treatment of Ischemic Heart Disease Li T, Matsuzaki M, and Hamano K .....	201
Effect of Bone Marrow Transplantation in Patients with Critical Limb Ischemia Katsuda Y, Takeshita Y, Arima K, Saitoh Y, Sasaki K, Shintani S, Murohara T, Imaizumi T .....	213
Therapeutic Angiogenesis for a Patient with Arteriosclerosis Obliterans by Autologous Transplantation of Bone Marrow Mononuclear Cells Fujimoto K, Miyagi H, Miyao Y, Kajiwara I, Oe Y, Kawano F, Hidaka M .....	221
Autologous Bone Marrow Implantation for Burger's Disease Ohtani M, Soma T, and Taguchi A .....	227
Closing Remarks .....	235
Index .....	237

# Dimeric Interaction between the Cytoplasmic Domains of the Na<sup>+</sup>/H<sup>+</sup> Exchanger NHE1 Revealed by Symmetrical Intermolecular Cross-Linking and Selective Co-immunoprecipitation<sup>†</sup>

Takashi Hisamitsu,<sup>‡</sup> Tianxiang Pang,<sup>‡</sup> Munekazu Shigekawa,<sup>§</sup> and Shigeo Wakabayashi<sup>\*:‡</sup>

Department of Molecular Physiology, National Cardiovascular Center Research Institute, Suita, Osaka 565-8565, Japan, and Department of Human Life Sciences, Senri Kinran University, Suita, Osaka 565-0873, Japan

Received April 1, 2004; Revised Manuscript Received June 24, 2004

**ABSTRACT:** To investigate the oligomeric structure of Na<sup>+</sup>/H<sup>+</sup> exchanger 1 (NHE1), permeabilized cells and membranes from cells expressing NHE1 variants were treated with the oxidizing agent Cu<sup>2+</sup>/*o*-phenanthroline or the bifunctional sulfhydryl reagent methanethiosulfonate. These treatments resulted in symmetrical intermolecular cross-linking at intrinsic (Cys<sup>794</sup> and Cys<sup>561</sup>) or 15 exogenous cysteine residues introduced into the distal carboxyl- (C-) terminal cytoplasmic domain (after aa 600) but not at intrinsic Cys<sup>538</sup> because of masking by its tight association with calcineurin B-homologous protein. Cross-linking was abolished in membranes solubilized with sodium dodecyl sulfate, which dissociates oligomeric NHE1, while it was preserved in those treated with Triton X-100. In addition, treatment with cross-linkers did not produce the tetrameric forms of NHE1 mutants with two cysteine residues. Thus, cross-linking presumably occurs between adjacent C-termini of the NHE1 dimer but not by a stochastic process via random collision of NHE1 molecules. The observations suggest that at least the distal C-termini of the NHE1 dimer are flexible or mobile and are thereby capable of easily making contact with each other over the large cytoplasmic portion of the molecule. Furthermore, co-immunoprecipitation experiments showed that the proximal C-termini (aa 503–580) have a strong propensity to interact directly with each other in parallel. Deletion of aa 562–579 resulted in disruption of disulfide cross-linking between the C-termini and markedly reduced the intracellular pH sensitivity of Na<sup>+</sup>/H<sup>+</sup> exchange, suggesting that the dimeric interaction in this region may control the pH-dependent regulation of NHE1.

The Na<sup>+</sup>/H<sup>+</sup> exchangers (NHEs,<sup>1</sup> SLC9 family) are electroneutral transporters that catalyze the exchange of Na<sup>+</sup> and H<sup>+</sup> in plasma membranes or other intracellular organellar membranes in various animal species (1–5). To date, nine NHE isoforms encoded by different genes have been identified in mammalian tissues, and these isoforms are

thought to play different roles in various tissues or in various organellar compartments. The first isoform to be cloned, NHE1 (6), is expressed ubiquitously in the plasma membranes of essentially all tissues and plays a major role in maintaining pH<sub>i</sub> and cell volume homeostasis. NHE1 consists of two large functional domains, an amino- (N-) terminal membrane domain (~500 amino acids) containing 12 putative membrane-spanning domains and a long carboxyl- (C-) terminal cytoplasmic domain (~300 amino acids). The N-terminal membrane domain catalyzes substrate transport, while the C-terminal domain is involved in regulation (7).

The activity of NHE1 is controlled by various extrinsic factors, including growth factors, hormones, and mechanical stimuli, presumably through the H<sup>+</sup>-regulatory site (1–6, 8). Such pH-dependent regulation is thought to occur through the interaction of the C-terminal domain with various signaling molecules (1–5). For example, calcineurin B-homologous protein (CHP) was identified as such an accessory protein that associates tightly with NHE1 (9). Recently, we reported that CHP serves as an essential cofactor for the physiological Na<sup>+</sup>/H<sup>+</sup> exchange activity through interaction with the juxtamembrane region of the C-terminal domain (10). Other factors in addition to CHP, including Ca<sup>2+</sup>/calmodulin (11, 12), an adaptor protein 14-3-3 (13), Nck-interacting kinase NIK (14), phosphatidyli-

<sup>†</sup> This work was supported by Grant-in-Aid for Priority Areas 13142210 and Grant-in-Aid 14580664 for Scientific Research from the Ministry of Education, Science, and Culture of Japan, by the promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research of Japan (Promotion of Fundamental Studies in Health Science), and by Grant nano-001 for Research on Advanced Medical Technology from the Ministry of Health, Labor, and Welfare of Japan. T.P. was supported by a Japan Society for the Promotion of Science Postdoctoral Fellowship.

<sup>\*</sup> To whom correspondence should be addressed. Tel: +81-6-6833-5012. Fax: +81-6-6835-5314. E-mail: wak@ri.ncvc.go.jp.

<sup>‡</sup> National Cardiovascular Center Research Institute.

<sup>§</sup> Senri Kinran University.

<sup>1</sup> Abbreviations: NHE, Na<sup>+</sup>/H<sup>+</sup> exchanger; CHP, calcineurin B homologous protein; pH<sub>i</sub>, intracellular pH; CuP, Cu<sup>2+</sup>/*o*-phenanthroline; MTS-2, 1,2-ethanediybis(methanethiosulfonate); MTS-6, 1,6-hexanediybis(methanethiosulfonate); MTS-17, 3,6,9,12,15-pentaoxaheptadecane-1,17-diylbis(methanethiosulfonate); MTSET, 2-(trimethylammonium)ethyl methanethiosulfonate; EIPA, 5-(*N*-ethyl-*N*-isopropyl)-amiloride; DMEM, Dulbecco's modified Eagle's medium; HEPES, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid; Tris, tris(hydroxymethyl)aminomethane; EDTA, ethylenediamine-*N,N,N',N'*-tetraacetic acid; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; DTT, dithiothreitol; SDS, sodium dodecyl sulfate; LDS, lithium dodecyl sulfate; aa, amino acid.

10.1021/bi049367x CCC: \$27.50 © 2004 American Chemical Society  
Published on Web 08/04/2004

inositol 4,5-bisphosphate (15), and carbonic anhydrase II (16), have been reported to associate with NHE1. However, as structural information is extremely limited even for the hydrophilic C-terminal domain, it is still difficult to determine the precise regulatory mechanism.

In addition to its regulatory aspect, NHE is known to exist as an oligomer in the plasma membrane. A previous study (17) showed that NHE1 and NHE3 form the homooligomers by interacting via the transmembrane regions in intact cells although the functional unit may still be monomeric. Consistent with this, NHE1 in the placental brush border membranes was detected as a larger form (~205 kDa) cross-linked by disulfide bonds (18). In addition, pre-steady-state kinetics revealed that Na<sup>+</sup>/H<sup>+</sup> exchange in kidney brush border membrane vesicles exhibits cooperative extracellular Na<sup>+</sup> dependence despite electroneutral exchange, suggesting that NHE may function as an oligomer (19–21). Electron cryomicroscopy using two-dimensional crystals indicated that the bacterial Na<sup>+</sup>/H<sup>+</sup> antiporter NhaA also appears to form dimers (22). However, at present, the physiological significance of this oligomerization is not well understood.

In the present study, we analyzed dimeric interactions between the cytoplasmic domains of NHE1. One aim of this study was to elucidate the structural features of the cytoplasmic domains of the NHE1 dimer. The second aim was to determine whether adjacent cytoplasmic domains of the NHE1 dimer interact directly with each other. We found that symmetrical intermolecular cross-linking at native or introduced cysteine residues occurs between the cytoplasmic domains of the NHE1 dimer and that the expressed cytoplasmic domains interact strongly with each other in cells. This is the first report indicating dimeric interaction between adjacent cytoplasmic domains of two NHE1 molecules.

## EXPERIMENTAL PROCEDURES

**Cell Culture and cDNA Transfection.** The exchanger-deficient cell line PS120 and corresponding transfectants were maintained in Dulbecco's modified Eagle's medium containing 25 mM NaHCO<sub>3</sub> and supplemented with 7.5% (v/v) fetal calf serum, penicillin (50 units/mL), and streptomycin (50 µg/mL). Cells were maintained at 37 °C in the presence of 5% CO<sub>2</sub>. All cDNA constructs were transfected into PS120 cells by the calcium phosphate–DNA coprecipitation technique, and stable clones were selected by repetitive H<sup>+</sup>-killing selection procedures as described previously (7).

**Construction of the NHE1 Mutant Plasmid.** The plasmid carrying a cDNA encoding NHE1 containing unique restriction sites cloned into the mammalian expression vector pECE was described previously (7). The cDNA construct for NHE1 in which all endogenous cysteine residues were replaced by alanine, designated as Cys-less NHE1, was also described previously (23). Construction of plasmids for NHE1 containing point mutations was carried out by a PCR-based strategy using two template plasmids encoding the wild-type or Cys-less NHE1 as described previously (23). Similarly, plasmids containing nucleotide sequences corresponding to the hemagglutinin (HA) epitope YPYDVPDYAS or the c-Myc epitope EQKLISEEDL were constructed by inserting PCR fragments produced using antisense primers containing either epitope sequence and a stop codon just after the C-terminus

of NHE1 into the appropriate restriction sites of the plasmid containing NHE1 cDNA. Expression vectors for the C-terminal cytoplasmic domain were constructed by a similar PCR-based strategy using HA- or Myc-tagged NHE1 plasmid as a template. The PCR products were inserted into pEGFP-N1 (Clontech, Palo Alto, CA), in which expression of green fluorescent protein (GFP) was blocked by introduction of a stop codon. Constructs were confirmed by sequencing plasmids with an ABI-PRISM DNA sequencer model 3100 (Applied Biosystems, Foster City, CA). In this study, we used the prefix "cl-" for point mutants produced from Cys-less NHE1 as a background.

**Cross-Linking between Cysteine Residues of NHE1.** For crude membrane preparation, PS120 cells stably expressing the NHE1 variants were grown to confluence on 100 mm culture dishes and collected with a cell scraper into 1.5 mL microtubes. The cells were then washed once with PBS containing 137 mM NaCl, 2.7 mM KCl, 9.6 mM Na<sub>2</sub>HPO<sub>4</sub>, and 1.5 mM KH<sub>2</sub>PO<sub>4</sub> at pH 7.4 and homogenized with a Physcotron for 30 s at 2800 rpm on ice. The homogenates were centrifuged for 5 min at 4000 rpm, and the supernatants were centrifuged again for 15 min at 50000 rpm. The pellets (crude membranes) were resuspended in PBS, and protein content was adjusted to 2–3 mg/mL.

The membranes (1–1.5 mg/mL) were treated with 100 µM CuP for 15 min at 4 °C. To stop the reaction, EDTA (final concentration, 5 mM) was added to the reaction mixture, and then the membranes were dissolved with LDS sample buffer (Invitrogen, San Diego, CA) and subjected to PAGE. For cross-linking experiments on cells, confluent cells were washed twice with 5 mL of PBSCM (PBS containing 0.1 mM CaCl<sub>2</sub> and 1 mM MgCl<sub>2</sub>, pH 7.4) and permeabilized for 15 min on ice with 30 µM β-escin (Sigma, St. Louis, MO) dissolved in medium (120 mM KCl, 2.5 mM MgCl<sub>2</sub>, and 25 mM HEPES, adjusted to pH 7.2 with KOH) as described previously (24). The permeabilized cells were washed to remove β-escin and incubated with 100 µM CuP for 15 min at 4 °C, and the reaction was stopped by treating cells with 10 mM *N*-ethylmaleimide (NEM). In some experiments, cells were treated directly with cysteine cross-linkers MTS-2, MTS-6, or MTS-17 in PBSCM. The resultant cells were solubilized with PBS containing 2% SDS, 20 mM NEM, and 5 mM EDTA, mixed with concentrated LDS sample buffer, and subjected to PAGE.

**Immunoprecipitation and Immunoblotting.** Cells were transiently transfected with the HA- or Myc-tagged C-terminal cytoplasmic domain of NHE1, and 48 h later cells were solubilized for 20 min on ice with lysis buffer (1% Triton X-100, 5 mM EDTA, 1 mM phenylmethanesulfonyl fluoride, and 1 mM benzamide in PBS) and then centrifuged at 15000 rpm for 5 min. The supernatant was incubated for 2 h at 4 °C with anti-tag antibody plus 30 µL of protein A–Sepharose beads (Amersham Biosciences Inc., Piscataway, NJ). The beads were washed five times with ice-cold lysis buffer, and proteins were eluted with LDS sample buffer containing 50 mM DTT. After PAGE on 3–8% gradient gels (Invitrogen) or handmade 7.5% gels (Figure 3), proteins were transferred electrophoretically onto poly(vinylidene difluoride) membranes and subjected to immunoblotting with anti-NHE1 (11), anti-HA (Santa Cruz Biotechnology Inc., Santa Cruz, CA), or anti-Myc polyclonal antibody (Santa Cruz) as described previously (11). Proteins were visualized




FIGURE 1: Cross-linking of NHE1 proteins with CuP. Crude membranes were prepared from cells expressing wild-type or Cys-less NHE1 and suspended in PBS at a protein concentration of 0.5–1 mg/mL. Membranes (60–90  $\mu$ g) were treated with CuP (final concentration, 100  $\mu$ M) for 15 min on ice, and then the reaction was stopped by adding EDTA (5 mM). In some experiments, membranes were briefly (5 min) treated with MTSET (1 mM) before CuP treatment. Samples of 12–18  $\mu$ g of protein per lane were subjected to PAGE followed by immunoblotting with NHE1-specific antibody under reducing (+DTT) or nonreducing conditions.

by enhanced chemiluminescence detection (Amersham). Data were usually represented as a typical example of three independent experiments.

**Measurement of  $^{22}\text{Na}$  Uptake.**  $^{22}\text{Na}^+$  uptake activity was measured by the  $\text{K}^+$ /nigericin  $\text{pH}_i$  clamp method (25). Briefly, serum-depleted cells in 24-well plates were preincubated for 30 min at 37  $^\circ\text{C}$  in  $\text{Na}^+$ -free choline chloride/KCl medium containing 20 mM HEPES/Tris (pH 7.4), 1.2–140 mM KCl, 2 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 5 mM glucose, and 5  $\mu$ M nigericin (Molecular Probes, Inc., Eugene, OR).  $^{22}\text{Na}^+$  uptake was started by adding the same choline chloride/KCl solution containing  $^{22}\text{NaCl}$  (37 kBq/mL; final concentration, 1 mM), 1 mM ouabain, and 0.1 mM bumetanide. In some wells, the uptake solution contained 0.1 mM EIPA. One minute later, cells were rapidly washed four times with ice-cold PBS to terminate  $^{22}\text{Na}^+$  uptake.  $\text{pH}_i$  was calculated from  $[\text{K}^+]_i/[\text{K}^+]_o = [\text{H}^+]_i/[\text{H}^+]_o$  by assuming an intracellular  $[\text{K}^+]$  of 120 mM. The data were normalized by the protein concentration, which was measured using a bicinchoninic assay system (Pierce Chemical Co., Rockford, IL) using bovine serum albumin as a standard.

## RESULTS

**Detection of the NHE1 Dimer by Symmetrical Intermolecular Cross-Linking at Cysteine Residues.** We first prepared crude membranes from cells expressing NHE1 or its cysteine-free derivative, Cys-less NHE1. Two protein bands were visible on immunoblotting with NHE1-specific antibody (Figure 1, lane 1). The upper band (~100–110 kDa) was the N- and O-linked glycosylated mature form, while the lower band (~80 kDa) was the immature form containing only high-mannose oligosaccharide (25). Following treatment of the membranes with the oxidizing agent CuP (100  $\mu$ M), the NHE1 monomer band disappeared and a new protein band became detectable within the higher molecular mass range of 200–230 kDa, which was twice that of the monomer (Figure 1, lane 3). We also performed similar experiments using membranes pretreated with endoglycosidase F, which is known to cleave N-linked glycans in NHE1 (26). Although endoglycosidase F treatment reduced the apparent molecular mass of NHE1 to 92–96 kDa, further





FIGURE 2: Effects of detergents on cross-linking of NHE1 with CuP. Crude membranes from PS120 cells expressing NHE1 were solubilized with or without 1% Triton X-100 (A) or 1% SDS (B). The solubilized membranes were centrifuged at 15000 rpm for 5 min to remove cell debris. Detergent-treated or untreated proteins were incubated with CuP (0–100  $\mu$ M) for 15 min at 4  $^\circ\text{C}$ . After the reaction was stopped with EDTA, proteins were separated on PAGE under nonreducing conditions and subjected to immunoblotting with anti-NHE1 antibody. D and M indicate the positions of the NHE1 dimer and monomer, respectively.

CuP treatment resulted in a similar mobility shift to a higher molecular mass range (175–200 kDa), which was again twice that of the monomer (data not shown). The mobility shift was abolished almost completely by treatment with 10 mM DTT after oxidation or pretreatment with 1 mM cysteine-directed modifier reagent MTSET (Figure 1). In addition, this shift was not observed in Cys-less NHE1 (Figure 1). We also verified that the mature NHE1 expressed in the plasma membrane was cross-linked after surface labeling with NHS-biotin (data not shown). These results suggested that CuP treatment resulted in intermolecular disulfide bond formation at cysteine residues derived presumably from two NHE1 molecules. It should be noted that cross-linking between the immature forms of NHE1 was not detected in this experiment (Figure 1). However, it was often detected when we used membrane preparations including immature forms in relatively high quantities (Figures 2 and 5).

Cross-linking experiments suggested that two NHE1 monomers make contact with each other in the membrane. It is of interest to determine whether their interaction is preserved in the presence of detergents. Membranes were solubilized with 1% Triton X-100 or 1% SDS. After centrifugation the supernatant was treated with CuP and analyzed on immunoblot. As shown in Figure 2, the CuP-induced mobility shift of NHE1 on PAGE occurred in the presence of the relatively mild detergent Triton X-100 but not the more harsh detergent SDS. These findings suggested that two NHE1 monomers are still capable of interacting with each other upon treatment with Triton X-100 but not with SDS. Thus, it is unlikely that disulfide cross-linking is simply dependent on stochastic random collision.


**Intermolecular Disulfide Cross-Linking Occurs between Cysteine Residues in Two Adjacent C-Terminal Cytoplasmic Domains of NHE1 Dimers.** To identify the cysteine residue(s) that participate in cross-linking, we constructed NHE1



**FIGURE 3:** Cross-linking of NHE1 proteins containing a single cysteine residue. Crude membranes were prepared from cells stably expressing wild-type, Cys-less, mutants with a single native cysteine residue (A) or mutants with a single cysteine residue introduced into Cys-less NHE1 (B) and treated with 100  $\mu$ M CuP for 15 min at 4  $^{\circ}$ C. The resulting membranes were analyzed by immunoblotting with the anti-NHE1 antibody under reducing or nonreducing conditions. Mutants with the native cysteine residue are indicated by an asterisk.

mutants with a single intrinsic cysteine residue using Cys-less NHE1 as the background template plasmid. Disulfide cross-linking with CuP did not occur at Cys<sup>8</sup> in the cytoplasmic N-tail or at Cys<sup>113</sup>, Cys<sup>133</sup>, Cys<sup>212</sup>, Cys<sup>421</sup>, or Cys<sup>477</sup> in the membrane-spanning domains (Figure 3A), consistent with our previous observation that the latter membranous cysteine residues are not accessible to the sulfhydryl reagent biotin maleimide (23). In contrast, cross-linking was observed at position 794 in the C-terminal cytoplasmic domain of NHE1 (Figure 3A). Significant but somewhat weaker cross-linking was also observed at position 561 but not at position 538. These results indicated that cross-linking of NHE1 occurs mainly at Cys<sup>794</sup>. It should be noted that the apparent molecular mass (250 kDa or more) of cross-linked C561\* was unexpectedly higher than the calculated mass of the NHE1 dimer. We considered it likely that cross-linking between juxtamembrane cysteine residues of NHE1 leads to a structural change resulting in aberrantly slow migration on PAGE.


We introduced a single exogenous cysteine mutation into several positions of the cytoplasmic domain of NHE1. Surprisingly, in addition to native cysteine residues Cys<sup>794</sup> and Cys<sup>561</sup>, CuP induced intermolecular cross-linking at various cytoplasmic amino acid positions, i.e., 603, 625, 680, 760, 793, 800 (Figure 3B), 615, 638, 650, 661, 701, 720, 740, 760, and 780 (data not shown), but not at position 520



**FIGURE 4:** Cross-linking of NHE1 and its derivatives in permeabilized cells. (A) Cells stably expressing NHE1 or its Cys-less form were permeabilized with  $\beta$ -escin and then treated with 100  $\mu$ M CuP for 15 min on ice and analyzed by immunoblotting with anti-NHE1 antibody under reducing and nonreducing conditions. (B) Permeabilized cells stably expressing C794\* were treated with CuP, MTS-2, or MTS-17 (100  $\mu$ M each) for 15 min on ice and analyzed by immunoblotting. (C) Cells stably expressing NHE1 mutants with a native cysteine residue or various derivatives of CHP-binding-defective mutant 4Q were permeabilized with  $\beta$ -escin, then treated with 100  $\mu$ M CuP for 15 min on ice, and analyzed by immunoblotting with anti-NHE1 antibody. In 4Q, four hydrophobic residues of NHE1, Phe<sup>526</sup>, Leu<sup>527</sup>, Leu<sup>530</sup>, and Leu<sup>531</sup>, were replaced by four glutamine residues (10).

(Figure 3B) (see also Figure 10 for amino acid positions in NHE1). We also tested cross-linking with CuP using  $\beta$ -escin-permeabilized cells, which are thought to maintain more natively like conditions. As shown in Figure 4A, CuP-induced, DTT-dependent cross-linking was observed in permeabilized cells expressing wild-type NHE1 but not Cys-less NHE1. We also detected similar cross-linking in permeabilized cells expressing the NHE1 mutants with exogenous cysteine residues described above (not shown). Using permeabilized cells expressing C794\*, we also tested other bifunctional cysteine cross-linkers, MTS-2 and MTS-17, which have spacer lengths of 5 and 25  $\text{\AA}$ , respectively. These agents were as effective as CuP for cross-linking of C794\* (Figure 4B). Thus, the intermolecular cross-linking at cysteine residues from two NHE monomers appears to occur independently of cross-linker spacer length over the large cytoplasmic portion.


We postulated that lack of cross-linking of cysteine residues (positions 520 and 538) in the juxtamembrane domain may be due to the presence of CHP, which was shown to interact strongly with this region (10). We constructed several cysteine mutant NHE1s using the Cys-less version of 4Q that was reported previously to abolish CHP binding (10). As expected, in contrast to C538\* (see Figure 4C), CuP treatment induced cross-linking in cells expressing C538\*-4Q as well as other mutants, C561\*-4Q and C794\*-4Q (Figure 4C), suggesting that cross-linking at position 538 is masked by the presence of bound CHP. It should be noted that the apparent molecular masses for cross-linked products of C538\*-4Q and C561\*-4Q were higher than that for C794\*-4Q (Figure 4C; see also Figure 3).



**FIGURE 5:** Cross-linking of the double-cysteine mutant of NHE1. (A) Cells expressing the NHE1 mutant (cl-Y381C/C794\*) with two cysteine residues at positions 381 and 794 were first treated with 100  $\mu$ M MTS-2 for 15 min on ice, and then crude membranes were prepared. Membranes were further treated with 100  $\mu$ M CuP for 15 min at 4  $^{\circ}$ C and analyzed by PAGE under reducing and nonreducing conditions followed by immunoblotting with anti-NHE1 antibody. (B) Schematic drawing showing the possible cross-linking between cysteine residues of two NHE1 monomers.

We further analyzed the oligomerization of NHE1 using cells expressing a mutant with two cysteine residues at amino acid positions 381 and 794; the former (Tyr in wild-type NHE1) is located in the extracellular loop 5 (23), while the latter is located in the cytosol. In a preliminary search, we found that cysteines at 381 (and also at 153 and 283) can form intermolecular cross-links on treatment with the un-cleavable cross-linker MTS-2. This reagent was not accessible to Cys<sup>794</sup> from the outside of living cells at least under our experimental conditions (not shown). Treatment of cells expressing this double cysteine mutant with MTS-2 produced the DTT-insensitive protein band at the dimer position on PAGE (Figure 5A, lane 6), suggesting that the intermolecular cross-linking occurred at cysteines introduced into position 381, as shown schematically in Figure 5B. After treatment with MTS-2, crude membranes were prepared. Further treatment of membranes with CuP increased the intensity of the protein band at the dimer position but did not produce the protein band with higher molecular mass corresponding to the tetrameric form (i.e., dimer of dimers) (Figure 5A, lane 8), suggesting that cytoplasmic cross-linking does not occur between dimers cross-linked externally (Figure 5B).


**Direct Interaction between the Cytoplasmic Domains of NHE1.** Cross-linking experiments suggested that the cytoplasmic domains of NHE1 may be located in close proximity. To test whether the cytoplasmic domains of NHE1 make contact with each other homotypically, we transiently co-expressed two cytoplasmic domains (aa 503–815) with



**FIGURE 6:** Co-immunoprecipitation of the C-terminal cytoplasmic domains of NHE1 labeled with different tags. Two plasmids, 503–815-HA and 503–815-Myc, were transiently cotransfected into PS120 cells. Forty-eight hours after transfection, Triton X-100-solubilized proteins were subjected to immunoprecipitation (IP) with anti-HA or anti-Myc antibodies followed by immunoblotting (IB). Proteins were also analyzed without immunoprecipitation (lanes 3 in both panels).

different tags, HA and Myc, in PS120 cells (see Figure 6). These proteins were expressed well as shown by immunoblotting with each specific antibody, although shorter bands (~35 kDa) were also visible (Figure 6, lane 3 in left and right panels). We observed that the upper bands bind CHP, while the lower bands do not (data not shown). As CHP binds to the juxtamembrane domain (aa 510–540), the former is probably the full-length cytoplasmic domain although its apparent molecular mass (~48 kDa) is higher than the calculated value (~37 kDa), while the latter may be the N-terminally degraded protein. The HA- and Myc-tagged cytoplasmic domain proteins were recovered in the immunoprecipitates with Myc- and HA-specific antibodies (Figure 6, lane 1 in left and lane 2 in right), respectively, suggesting that the two expressed cytoplasmic domains interacted with each other in cells.

Interestingly, tag-specific antibodies did not co-immunoprecipitate the shorter, possibly degraded fragments (Figure 6), suggesting that the N-terminus is important for interaction between the cytoplasmic domains. To identify the site of interaction, we constructed epitope-tagged cytoplasmic domains of different sizes and performed co-immunoprecipitation experiments. Deletion of the N-terminus up to aa 580 abolished co-immunoprecipitation, while deletion up to aa 562 preserved it (Figure 7B). Therefore, at least aa 562–580 is important for the interaction between cytoplasmic domains, but aa 580–815 is not involved. Similar experiments were repeated with combinations of cytoplasmic domains of different sizes. While 562–815-Myc interacted with 503–815-HA, the same protein did not interact with 503–815( $\Delta$ 562–579)-HA (Figure 8B, parts a and b), indicating that aa 562–579 binds to the same region of the partner protein. Thus, the region 562–579 appears to be crucial for interaction. Furthermore, the cytoplasmic domains deleted of aa 540–579 were also capable of interacting with each other (Figure 8B, part d). In addition, 503–815-Myc interacted with 503–815( $\Delta$ 562–579)-HA (Figure 8B, part e) and 503–815( $\Delta$ 540–579)-HA (data not shown). Thus,



**FIGURE 7:** Co-immunoprecipitation of the various cytoplasmic domains of NHE1 labeled with different tags. (A) Schematic drawing of cytoplasmic domain constructs. (B) The two plasmids indicated in the figure were transiently transfected into PS120 cells. Triton X-100-solubilized proteins were subjected to immunoprecipitation (IP) with anti-HA antibody followed by immunoblotting (IB) with anti-Myc or anti-HA antibody. Solubilized lysates without immunoprecipitation (input).


in addition to aa 562–579, the more proximal region also has the ability to interact.

We expressed an NHE1 mutant with deletion of part of the cytoplasmic interaction domain (aa 562–579) in PS120 cells and carried out the cross-linking experiment using the crude membrane fraction. In contrast to the appearance of a discrete dimer band for wild-type NHE1, CuP treatment resulted in smears on the gel for  $\Delta 562-579$  (Figure 9A), suggesting that this mutant protein may form complexes with other cellular proteins through Cys<sup>794</sup>. Thus, deletion of aa 562–579 markedly inhibited the intermolecular cross-linking between the NHE1 monomers. It should be noted that CuP treatment also produced relatively discrete, cross-linked products with lower molecular mass (~150 kDa), which were presumably derived from the immature form of  $\Delta 562-579$ .

We next measured the EIPA-sensitive <sup>22</sup>Na<sup>+</sup> uptake in transfectants stably expressing wild-type or  $\Delta 562-579$ . Deletion of aa 562–579 reduced the maximal activity at acidic pH<sub>i</sub> by about 10-fold (not shown). Furthermore, the same deletion greatly shifted the pK value for intracellular pH to the acidic side as compared to wild-type NHE1 (Figure 9B) and abolished NHE1 activation in response to various stimuli, such as growth factors and hyperosmotic stress (data not shown). These observations suggested that this region is critical for preserving the pH-dependent regulation of NHE1.

## DISCUSSION

This study was initiated on the basis of our finding that NHE1 in the membranes can be cross-linked with the zero-length cross-linker CuP. Treatment of permeabilized cells or membranes expressing various NHE1 variants with CuP



**FIGURE 8:** Co-immunoprecipitation performed on different combinations of the various cytoplasmic domains of NHE1. (A) Schematic drawing of cytoplasmic domain constructs. (B) The two plasmids indicated in the figure were transiently transfected into PS120 cells. Detergent-solubilized proteins were subjected to immunoprecipitation (IP) with anti-HA antibody followed by immunoblotting (IB) with anti-Myc antibody. Solubilized lysates without immunoprecipitation (input).

or other MTS reagents resulted in a mobility shift of NHE1 from the monomer to the higher molecular mass range corresponding to the dimer. We also showed that treatment of a double-cysteine mutant NHE1 (positions 381 and 794) with two different cross-linkers did not produce the higher molecular mass products corresponding to the tetrameric form (see Figure 5). The latter observation suggests that two NHE1 dimers are not further cross-linked with each other at the cytoplasmic end. These observations were consistent with the previous findings that treatment of cells with the amino-directed cross-linker disuccinimidyl suberate resulted in production of homodimeric forms of NHE1 or NHE3 (17) and that intermolecular disulfide cross-linking of NHE1 occurred in the placental brush border membranes (18). A previous study (17) indicated that homodimers would be formed somewhere between the N-terminal transmembrane domains of NHE1 (aa 1–500). Unexpectedly, we found that intermolecular cross-linking occurred predominantly at Cys<sup>794</sup> in the C-terminal cytoplasmic domain, suggesting that, in addition to the transmembrane domain, the two C-termini of the NHE1 dimer might be located in close proximity.

One important observation is that CuP-induced cross-linking of NHE1 occurred even when membranes were solubilized with Triton X-100 (Figure 2A), suggesting that the NHE1 dimer did not dissociate on solubilization with this detergent. Such a strong interaction between monomers was also reported in the bacterial Na<sup>+</sup>/H<sup>+</sup> antiporter NhaA,

## Association of Genetic Polymorphisms of Sodium-Calcium Exchanger 1 Gene, *NCX1*, with Hypertension in a Japanese General Population

Yoshihiro KOKUBO<sup>\*1</sup>, Nozomu INAMOTO<sup>\*1</sup>, Hitonobu TOMOIKE<sup>\*1</sup>, Kei KAMIDE<sup>\*2</sup>, Shin TAKIUCHI<sup>\*2</sup>, Yuhei KAWANO<sup>\*2</sup>, Chihiro TANAKA<sup>\*3</sup>, Yuki KATANOSAKA<sup>\*3</sup>, Shigeo WAKABAYASHI<sup>\*3</sup>, Munekazu SHIGEKAWA<sup>\*3</sup>, Otosaburo HISHIKAWA<sup>\*4</sup>, and Toshiyuki MIYATA<sup>\*3</sup>

The Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (NCX) is a membrane protein involved in calcium homeostasis, catalyzing the exchange of one Ca<sup>2+</sup> ion for three Na<sup>+</sup> ions across the cell membrane. The Na<sup>+</sup>/Ca<sup>2+</sup> exchange has been suggested to play a role in the pathogenesis of hypertension. Therefore, we examined whether genetic variations in *NCX1* were associated with hypertension. Among 15 polymorphisms identified in 96 hypertensive subjects by sequencing the entire exon and promoter regions of *NCX1*, 7 representative polymorphisms with a minor allele frequency of greater than 4% were genotyped in 1,865 individuals, of whom 787 were hypertensive and 1,072 were normotensive. These subjects were residents of Suita City and were randomly selected as a population for the Suita cohort study. Multivariate logistic regression analysis performed after adjusting for age, body mass index, hyperlipidemia, diabetes mellitus, smoking, and drinking revealed that the -23200T>C and -23181T>C polymorphisms in the 5' upstream region of exon 1c were significantly associated with hypertension in men (-23200T>C: CC vs. TC+TT: odds ratio=0.61; 95% confidence intervals: 0.39 to 0.97; *p*=0.04) and in women (-23181T>C: CC vs. TC+TT: odds ratio=1.45; 95% confidence intervals: 1.04 to 2.02; *p*=0.03), respectively. Thus, our study suggests that *NCX1* is one of the genes related to susceptibility to essential hypertension in the Japanese general population.

(*Hypertens Res* 2004; 27: 697-702)

**Key Words:** *NCX1*, Na<sup>+</sup>/Ca<sup>2+</sup> exchanger, gene variants, hypertension

### Introduction

The Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (NCX) is an important membrane protein involved in calcium homeostasis in various cell types and catalyzes the electrogenic exchange of one Ca<sup>2+</sup> ion for three Na<sup>+</sup> ions across the plasma membrane (1-3). The Na<sup>+</sup>/

Ca<sup>2+</sup> exchange has been well demonstrated to play a role in the pathogenesis of hypertension. Blaustein *et al.* suggested that excessive Na<sup>+</sup> retention may secrete an ouabain-like substance that increases the cytosolic Na<sup>+</sup> concentration by inhibiting the plasmalemmal Na<sup>+</sup>-pump, which increases the cytosolic Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>) by reducing Ca<sup>2+</sup>-extrusion via Na<sup>+</sup>/Ca<sup>2+</sup> exchange (4-6). The increase in arteri-

From the <sup>\*1</sup>Division of Preventive Cardiology, <sup>\*2</sup>Division of Hypertension and Nephrology, and <sup>\*3</sup>Research Institute, National Cardiovascular Center, Suita, Japan, and <sup>\*4</sup>Suita City Medical Association, Suita, Japan.

This study was supported by the Program for Promotion of Fundamental Studies in Health Science of the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan MPJ-3.

Address for Reprints: Yoshihiro Kokubo, M.D., Ph.D., Division of Preventive Cardiology, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan. E-mail: yokokubo@hsp.ncvc.go.jp

Received March 2, 2004; Accepted in revised form June 4, 2004.




FIGURE 9: Properties of deletion mutant  $\Delta 562-579$  of NHE1. (A) Membranes were prepared from cells expressing wild-type NHE1 or deletion mutant  $\Delta 562-579$ , then treated with  $50 \mu\text{M}$  CuP for 0.5–15 min on ice, and analyzed by immunoblotting with anti-NHE1 antibody. A typical example of three independent experiments was shown. (B) The  $\text{pH}_i$  dependence of  $^{22}\text{Na}^+$  uptake in cells expressing wild-type NHE1 or deletion mutant  $\Delta 562-579$  was measured as described in Experimental Procedures.

which did not dissociate on solubilization with dodecyl maltoside (27). However, CuP-induced cross-linking was abolished when membranes were solubilized with the harsher detergent SDS, which is expected to dissociate the NHE1 dimer (Figure 2B). These observations suggest that dimerization is not a stochastic process resulting from random collisions between monomers.

We found that CuP-induced cross-linking of NHE1 occurs predominantly at Cys<sup>794</sup> and weakly at Cys<sup>561</sup>. Surprisingly, such symmetrical cross-linking was also observed between almost all cysteine residues introduced into the distal C-terminal region (amino acid positions 615, 625, 638, 650, 661, 680, 701, 720, 740, 760, 780, and 800), suggesting that two C-termini are able to make contact at various cytoplasmic sites, despite the interaction of various signaling molecules with this region of NHE1. This unusual phenomenon, however, does not appear to be due to artifacts resulting from protein denaturation or aggregation because cross-linking at multiple sites also occurred in permeabilized cells which are expected to preserve the relatively intact membrane integrity and because biotin-labeled surface NHE1 proteins were also cross-linked in a similar way (see Results). We observed that CuP-induced cross-linking between Cys<sup>538</sup> residues does not occur normally but becomes detectable when CHP binding is disrupted by mutation (4Q) (Figure 4D), suggesting that tightly bound CHP sterically blocks the homotypic interaction between CHP-binding domains (aa 510–540) of wild-type NHE1. Although  $\text{Ca}^{2+}$ /calmodulin (11, 12), 14-3-3 (13), tescalcin (28, 29), carbonic anhydrase II (16), and heat shock protein (30) were reported to bind to several regions within the distal C-terminal domain, the results of




FIGURE 10: Possible dimer model of NHE1. Positions of amino acid residues mutated in this study were indicated. The region aa 562–579 would confer dimerization of the cytoplasmic regulatory domain. Although the region aa 503–540 has also the ability to interact with each other, it would not make contact in the mature NHE1 expressed in the plasma membrane because CHP tightly associates with this region. The distal region (aa 600–815) would have a flexible structure.

the present study suggest that, unlike CHP, these proteins may interact with NHE1 only in a spatially or temporally restricted fashion.

In addition to CuP treatment, cross-linking at intrinsic or other introduced cysteine residues also occurred upon treatment with the thiol-directed cross-linkers MTS-2 and MTS-17, the spacer arms of which have lengths of 5 and 25 Å, respectively (31). These observations strongly suggest that the distal C-terminus of NHE1 has a flexible structure (Figure 10), thereby allowing the distance between the cytoplasmic domains of the NHE1 dimer to change easily. The distal regions thus do not directly interact, consistent with the recent result that the last C-terminal 183 amino acids of NHE1 have only a slight tendency to dimerize on their own (29). On the basis of circular dichroism measurements, Li et al. (29) reported that the distal region of NHE1 contains essentially a  $\beta$ -sheet,  $\beta$ -turn, and an unstructured part, but almost no  $\alpha$ -helix, and that the secondary structure is significantly altered upon changes in pH or  $\text{Ca}^{2+}$  concentration. The high degree of flexibility of the NHE1 cytoplasmic domain may play an important role in its function. Previously, we proposed that  $\text{Ca}^{2+}$ -induced activation of NHE1 occurs through derepression of the autoinhibitory domain (aa 635–656) caused by calmodulin binding (11, 12). The mobile cytoplasmic domain might provide structural benefits for such a  $\text{Ca}^{2+}$ -induced activation because the autoinhibitory domain is predicted to interact with an acceptor region(s) within the transmembrane domain of NHE1 in the resting state and to leave the putative acceptor in response to  $\text{Ca}^{2+}$  mobilization (32). In addition, NHE1 may control actin cytoskeletal reorganization through interaction with ERM family proteins (33), thereby regulating stress fiber formation and cell locomotion (33–35). Two different functions of NHE1, ion exchange and cytoskeletal rearrangement, appear to be regulated independently (33–35). Flexibility of the

cytoplasmic domain may help to alleviate constraints on the transmembrane ion transport domain, which may be produced by interaction with the cytoskeleton. Some degree of flexibility was also observed in the N-terminal cytoplasmic domain of the anion exchanger AE1 (band 3), which is known to bind the membrane-cytoskeleton anchoring protein ankyrin (36, 37), although this domain of AE1 has a relatively compact dimeric structure (38). It is interesting to note that, in contrast to NHE1, intermolecular cross-linking occurs between two different endogenous cysteine residues, Cys<sup>201</sup> and Cys<sup>317</sup>, in the cytoplasmic domain of AE1 (39).

The structure of the proximal C-terminal region of NHE1 appears to be quite different from the distal end of the molecule. We found that the expressed C-terminal domains interact strongly in cells through several sites within aa 503–580. The requirement of symmetrical regions within aa 503–580 for the interaction (Figure 8) suggests that this homotypic association is specific and not due to nonspecific binding or aggregation. These observations indicate that this region (aa 503–580) of NHE1 has a strong propensity to interact with the same region in adjacent molecules in a parallel fashion. Thus, in addition to the transmembrane domains (17), this cytoplasmic region may be another candidate for the dimer interface. However, it was difficult to determine whether these regions of the NHE1 dimer interact when the whole NHE1 is expressed in the plasma membrane. The CuP-induced Cys<sup>538</sup>-Cys<sup>538</sup> cross-linking of NHE1 was blocked by tightly bound CHP (Figure 4D). In addition, purified CHP complexed with aa 503–545 of NHE1 was confirmed to be a monomer on gel filtration (40). Therefore, at least the N-terminal halves (aa 503–545) in aa 503–580 of NHE1 would not interact with each other in NHE1 expressed in the membrane (Figure 10). However, the C-terminal halves may associate because CuP-induced cross-linking occurred through Cys<sup>561</sup> (Figure 3B). Thus, the region aa 562–579 may confer dimerization of the cytoplasmic regulatory domain, which in turn appears to bring the remaining distal flexible portion (aa 580–815) of the respective monomers into close proximity of each other. Previously, we reported that deletions of different regions in subdomain I (aa 515–595) of the NHE1 cytoplasmic domain markedly disrupted the NHE1 function, particularly the pH<sub>i</sub> sensitivity (25). Here, we observed that deletion of aa 562–579 disrupted the intermolecular disulfide cross-linking of NHE1 and shifted the pH<sub>i</sub> dependence of the exchange activity to the acidic side (Figure 9), suggesting that deletion-induced inhibition of NHE1 activity may be due to the structural distortion caused by disruption of dimeric interaction in this subdomain. These observations raise the interesting possibility that NHE1 may function as a cooperative dimer in which two subunits are functionally coupled in the regulation of pH<sub>i</sub> sensitivity. This was reinforced by our recent finding that intermolecular cross-linking at cysteine residues introduced into the extracellular loop abolished pH<sub>i</sub> regulation by NHE1 (T. Hisamitsu, unpublished observations).

It is also possible that the parallel association between the relatively long juxtamembrane regions (aa 503–580) has some other important physiological roles in the function of NHE1. These relatively hydrophobic stretches of two NHE1 monomers may be masked by interacting with each other during biosynthesis of NHE1, thereby passing the “quality control” checkpoint of the endoplasmic reticulum (ER).

Control of retention/retrieval in the ER by oligomerization has been demonstrated previously for some membrane proteins, such as ATP-sensitive potassium channels (41),  $\gamma$ -aminobutyric acid receptor (42), and *N*-methyl-D-aspartate receptor (43). Recently, we obtained some evidence that CHP does not bind to the immature form of NHE1 which is retained in the ER (our unpublished results). Therefore, it is plausible that NHE1 and CHP are capable of interacting only after these proteins are separately transported to the plasma membrane. The finding that the immature form of  $\Delta$ 562–579 can be cross-linked (Figure 9) suggests that the more proximal CHP-binding regions may dimerize in the ER but not in the plasma membrane.

In summary, we obtained evidence that the distal C-terminal cytoplasmic regions of the NHE1 dimer are flexible and that they are able to make contact easily, while the proximal regions have the intrinsic ability to interact directly with each other. To date, attempts to crystallize the cytoplasmic domain of NHE1 have been hampered by the high degree of degradation and aggregation of proteins expressed in *Escherichia coli* and other organisms, which may result from the unusual structural properties of the C-terminus. Although future studies are required to elucidate the precise structure, the results of the present study provide basic information regarding the dimeric structure of the C-terminal cytoplasmic domains of NHE1 expressed in living cells.

## ACKNOWLEDGMENT

We thank Ms. M. Okubo for technical assistance and Ms. K. Endo for manuscript preparation.

## REFERENCES

1. Wakabayashi, S., Shigekawa, M., and Pouyssegur, J. (1997) Molecular physiology of vertebrate Na<sup>+</sup>/H<sup>+</sup> exchangers, *Physiol. Rev.* **77**, 51–74.
2. Orłowski, L., and Grinstein, S. (2004) Diversity of the mammalian sodium/proton exchanger SLC9 gene family, *Pfluegers Arch.* **447**, 549–565.
3. Counillon, L., and Pouyssegur, J. (2000) The expanding family of eucaryotic Na<sup>+</sup>/H<sup>+</sup> exchangers, *J. Biol. Chem.* **275**, 1–4.
4. Putney, L. K., Denker, S. P., and Barber, D. L. (2002) The changing face of the Na<sup>+</sup>/H<sup>+</sup> exchanger, NHE1: structure, regulation, and cellular actions, *Annu. Rev. Pharmacol. Toxicol.* **42**, 527–552.
5. Slepokov, E., and Fliegel, L. (2002) Structure and function of the NHE1 isoform of the Na<sup>+</sup>/H<sup>+</sup> exchanger, *Biochem. Cell Biol.* **80**, 499–508.
6. Sardet, C., Franchi, A., and Pouyssegur, J. (1989) Molecular cloning, primary structure, and expression of the human growth factor-activatable Na/H antiporter, *Cell* **56**, 271–280.
7. Wakabayashi, S., Fafournoux, P., Sardet, C., and Pouyssegur, J. (1992) The Na<sup>+</sup>/H<sup>+</sup> antiporter cytoplasmic domain mediates growth factor signals and controls “H<sup>+</sup>-sensing”, *Proc. Natl. Acad. Sci. U.S.A.* **89**, 2424–2428.
8. Wakabayashi, S., Hisamitsu, T., Pang, T., and Shigekawa, M. (2003) Kinetic dissection of two distinct proton binding sites in Na<sup>+</sup>/H<sup>+</sup> exchangers by measurement of reverse mode reaction, *J. Biol. Chem.* **278**, 43580–43585.
9. Lin, X., and Barber, D. L. (1996) A calcineurin homologous protein inhibits GTPase-stimulated Na-H exchange, *Proc. Natl. Acad. Sci. U.S.A.* **93**, 12631–12636.
10. Pang, T., Su, X., Wakabayashi, S., and Shigekawa, M. (2001) Calcineurin homologous protein as an essential cofactor for Na<sup>+</sup>/H<sup>+</sup> exchangers, *J. Biol. Chem.* **276**, 17367–17372.
11. Bertrand, B., Wakabayashi, S., Ikeda, T., Pouyssegur, J., and Shigekawa, M. (1994) The Na<sup>+</sup>/H<sup>+</sup> exchanger isoform 1 (NHE1) is a novel member of the calmodulin-binding proteins, *J. Biol. Chem.* **269**, 13703–13709.

12. Wakabayashi, S., Bertrand, B., Ikeda, T., Pouyssegur, J., and Shigekawa, M. (1994) Mutation of calmodulin-binding site renders the Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE1) highly H<sup>+</sup>-sensitive and Ca<sup>2+</sup> regulation-defective. *J. Biol. Chem.* **269**, 13710–13715.
13. Lehoux, S., Abe, J., Florian, J. A., and Berk, B. C. (2001) 14-3-3 binding to Na<sup>+</sup>/H<sup>+</sup> exchanger isoform is associated with serum-dependent activation of Na<sup>+</sup>/H<sup>+</sup> exchange. *J. Biol. Chem.* **276**, 15794–15880.
14. Yan, W., Nehrke, K., Choi, J., and Barber, D. L. (2001) The Nck-interacting kinase (NIK) phosphorylates the Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1 and regulates NHE1 activation by platelet-derived growth factor. *J. Biol. Chem.* **276**, 31349–31356.
15. Aharonovitz, O., Zaun, H. C., Balla, T., York, J. D., Orlowski, J., and Grinstein, S. (2000) Intracellular pH regulation by Na<sup>+</sup>/H<sup>+</sup> exchanger requires phosphatidylinositol 4,5-bisphosphate. *J. Cell Biol.* **150**, 213–224.
16. Li, X., Alvarez, B., Casey, J. R., Reithmeier, R. A. F., and Fliegel, L. (2002) Carbonic anhydrase II binds to and enhances activity of the Na<sup>+</sup>/H<sup>+</sup> exchanger. *J. Biol. Chem.* **277**, 36085–36091.
17. Fournoux, P., Noël, J., and Pouyssegur, J. (1994) Evidence that Na<sup>+</sup>/H<sup>+</sup> exchanger isoforms NHE1 and NHE3 exist as stable dimers in membranes with a high degree of specificity for homodimers. *J. Biol. Chem.* **269**, 2589–2596.
18. Fliegel, L., Haworth, R. S., and Dyck, J. R. B. (1993) Characterization of the placental brush border membrane Na<sup>+</sup>/H<sup>+</sup> exchanger: identification of thiol-dependent transition in apparent molecular size. *Biochem. J.* **289**, 101–107.
19. Otsu, K., Kinsella, J., Sacktor, B., and Froehlich, J. P. (1989) Transient state kinetic evidence for an oligomer in the mechanism of Na<sup>+</sup>-H<sup>+</sup> exchange. *Proc. Natl. Acad. Sci. U.S.A.* **86**, 4818–4822.
20. Otsu, K., Kinsella, J. L., Heller, P., and Froehlich, J. P. (1993) Sodium dependence of the Na<sup>+</sup>-H<sup>+</sup> exchanger in the pre-steady state: implications for the exchange mechanism. *J. Biol. Chem.* **268**, 3184–3193.
21. Kinsella, J. L., Heller, P., and Froehlich, J. P. (1998) Na<sup>+</sup>/H<sup>+</sup> exchanger: proton modifier site regulation of activity. *Biochem. Cell Biol.* **76**, 743–749.
22. Williams, K. A. (2000) Three-dimensional structure of the ion-coupled transport protein NhaA. *Nature* **403**, 112–115.
23. Wakabayashi, S., Pang, T., Su, X., and Shigekawa, M. (2000) A novel topology model of the human Na<sup>+</sup>/H<sup>+</sup> exchanger isoform 1. *J. Biol. Chem.* **275**, 7942–7949.
24. Konishi, M., and Watanabe, M. (1995) Molecular size-dependent leakage of intracellular molecules from frog skeletal muscle fibers permeabilized with β-escin. *Pfluegers Arch.* **429**, 598–600.
25. Ikeda, T., Schmitt, B., Pouyssegur, J., Wakabayashi, S., and Shigekawa, M. (1997) Identification of cytoplasmic subdomains that control pH-sensing of the Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE1): pH-maintenance, ATP-sensitive, and flexible loop domains. *J. Biochem.* **121**, 295–303.
26. Counillon, L., Pouyssegur, J., and Reithmeier, R. A. F. (1994) The Na<sup>+</sup>/H<sup>+</sup> exchanger NHE-1 possesses N- and O-linked glycosylation restricted to the first N-terminal extracellular domain. *Biochemistry* **33**, 10463–10469.
27. Gerchman, Y., Rimon, A., Venturi, M., and Padan, E. (2001) Oligomerization of NhaA, the Na<sup>+</sup>/H<sup>+</sup> antiporter of *Escherichia coli* in the membrane and its functional and structural consequences. *Biochemistry* **40**, 3403–3412.
28. Mailänder, J., Müller-Esterl, W., and Dedio, J. (2001) Human homolog of mouse tescalcin associate with Na<sup>+</sup>/H<sup>+</sup> exchanger type-1. *FEBS Lett* **507**, 331–335.
29. Li, X., Liu, Y., Kay, C. M., Müller-Esterl, W., and Fliegel, L. (2003) The Na<sup>+</sup>/H<sup>+</sup> exchanger cytoplasmic tail: structure, function, and interactions with tescalcin. *Biochemistry* **42**, 7448–7456.
30. Silva, N. L., Haworth, R. S., Singh, D., and Fliegel, L. (1995) The carboxy-terminal region of the Na<sup>+</sup>/H<sup>+</sup> exchanger interacts with mammalian heat shock protein. *Biochemistry* **34**, 10412–10420.
31. Green, N. S., Reisler, E., and Houk, K. N. (2001) Quantitative evaluation of the length of homobifunctional protein cross-linking reagents used as molecular rulers. *Protein Sci.* **10**, 1293–1304.
32. Wakabayashi, S., Ikeda, T., Iwamoto, T., Pouyssegur, J., and Shigekawa, M. (1997) Calmodulin-binding autoinhibitory domain controls “pH-sensing” in the Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1 through sequence-specific interaction. *Biochemistry* **36**, 12854–12861.
33. Denker, S. P., Huang, D. C., Orlowski, J., Furthmayr, H., and Barber, D. L. (2000) Direct binding of the Na-H exchanger NHE1 to ERM proteins regulates the cortical cytoskeleton and cell shape independently of H<sup>+</sup> translocation. *Mol. Cell* **6**, 1425–1436.
34. Denker, S. P., and Barber, D. L. (2002) Cell migration requires both ion translocation and cytoskeletal anchoring by the Na-H exchanger NHE1. *J. Cell Biol.* **159**, 1087–1096.
35. Lagana, A., Vadnais, J., Le, P. U., Nguyen, T. N., Laprade, R., Nabi, I. R., Noel, J. (2000) Regulation of the formation of tumor cell pseudopodia by the Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1. *J. Cell Sci.* **113**, 3649–3662.
36. Blackman, S. M., Hustedt, E. J., Cobb, C. E., and Beth, A. H. (2001) Flexibility of the cytoplasmic domain of the anion exchange protein, band 3, in human erythrocytes. *Biophys. J.* **81**, 3363–3376.
37. Zhou, J., and Low, P. S. (2001) Characterization of the reversible conformational equilibrium in the cytoplasmic domain of human erythrocyte membrane band 3. *J. Biol. Chem.* **276**, 38147–38151.
38. Zhang, D., Kiyatkin, A., Bolin, J. T., and Low, P. S. (2000) Crystallographic structure and functional interpretation of the cytoplasmic domain of erythrocyte membrane band 3. *Blood* **96**, 2925–2933.
39. Thevenin, B. J.-M., B. M. Willardson, S., and Low, P. S. (1989) The redox state of cysteines 201 and 317 of the erythrocyte anion exchanger is critical for ankyrin binding. *J. Biol. Chem.* **264**, 15886–15892.
40. Pang, T., Hisamitsu, T., Mori, H., Shigekawa, M., and Wakabayashi, S. (2004) Role of calcineurin B homologous protein in pH regulation by the Na<sup>+</sup>/H<sup>+</sup> exchanger 1: Tightly bound Ca<sup>2+</sup> ions as important structural elements. *Biochemistry* **43**, 3628–3636.
41. Zerangue, N., Schwappach, B., Jan, Y. N., and Jan, L. Y. (1999) A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane K (ATP) channels. *Neuron* **22**, 537–548.
42. Margeta-Mitrovic, M., Jan, Y. N., and Jan, L. Y. (2000) A trafficking checkpoint controls GABA(B) receptor heterodimerization. *Neuron* **27**, 97–106.
43. Pérez-Otaño, I., Schulteis, C. T., Contractor, A., Lipton, S. A., Trimmer, J. S., Sucher, N. J., and Heinemann, S. F. (2001) Assembly with the NR1 subunit is required for surface expression of NR3A-containing NMDA receptors. *J. Neurosci.* **21**, 1228–1237.

BI049367X

**Table 1. Basic Characteristics of Subjects in Suita, a Japanese Urban Population, 2002**

	Men (n=858)	Women (n=1,007)
Age (year)	66.3±11.1*	63.3±11.0*
Systolic blood pressure (mmHg)	131.9±19.5*	128.0±19.6*
Diastolic blood pressure (mmHg)	79.7±10.7*	76.6±10.7*
Body mass index (kg/m <sup>2</sup> )	23.3±3.0*	22.3±3.2*
Total cholesterol (mmol/l)	5.10±0.78	5.57±0.79*
HDL-cholesterol (mmol/l)	1.42±0.36	1.67±0.40*
Current smokers (%)	30.1 <sup>†</sup>	6.3 <sup>†</sup>
Current drinkers (%)	67.0 <sup>†</sup>	29.3 <sup>†</sup>
Present illness (%)		
Hypertension	47.4 <sup>†</sup>	38.2
Hyperlipidemia	27.4	55.2 <sup>†</sup>
Diabetes mellitus	12.6 <sup>†</sup>	5.2

Values are mean±SD or percentage. Hypertension indicates systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or antihypertensive medication; hyperlipidemia, total cholesterol ≥5.68 mmol/l (220 mg/dl) or antihyperlipidemia medication; diabetes, fasting plasma glucose ≥7.0 mmol/l (126 mg/dl) or non-fasting plasma glucose ≥11.1 mmol/l (200 mg/dl) or HbA1c ≥6.5% or antidiabetic medication. \**p*<0.05 between women and men by Student's *t*-test. <sup>†</sup>*p*<0.05 between women and men by  $\chi^2$  test. HDL, high-density lipoprotein.

al tone caused by high [Ca<sup>2+</sup>]<sub>i</sub> would thus result in an elevation of blood pressure. Indeed, several previous studies have reported that Na<sup>+</sup>/Ca<sup>2+</sup> exchange activity was altered in the renal arterioles or arterial smooth muscle of spontaneous or salt-sensitive hypertensive rats (7–11). However, it is unknown whether such a mechanism relates to the occurrence of essential hypertension.

Of three isoforms (NCX1–3) derived from different genes, NCX1 is predominantly expressed in the heart, neurons and renal tubules, but is expressed at lower levels in other tissues, including the smooth muscle, skeletal muscle, lung and spleen (1–3). The *NCX1* gene (*SLC8A1*) is located on human chromosome 2p22.1 and includes 12 exons (12). There are at least 12 splice variants generated in different combinations from six exons in a tissue-specific manner (13). In addition, five exons encode 5'-untranslated sequences that are under the control of three tissue-specific promoters (14–17).

This study was undertaken to identify genetic variations in *NCX1* in a group of hypertensive subjects, and to examine the association of these variations with the presence of hypertension in a general population. In contrast to other association studies, which often focus on a limited number of polymorphisms in a gene, our study evaluated the full array of coding- and promoter-sequence polymorphisms in *NCX1*.


## Methods

### Subjects of the Suita Population Study

The subjects of the Suita study consisted of 14,200 men and women (30 to 79 years of age), who had been randomly selected from the municipal population registry and stratified

by in consideration of gender and age (stratified in 10-year intervals). They were all invited, by letter, to receive medical and behavioral examinations every 2 years at the Division of Preventive Cardiology, National Cardiovascular Center, Japan. DNA from the leukocytes was collected from participants who visited the National Cardiovascular Center between May 2002 and February 2003. All of the participants were Japanese. Only those who gave written informed consent for genetic analyses were included in this study. The study protocol was approved by the Ethical Review Committee of the National Cardiovascular Center. In this study, the genotypes of 1,865 samples were determined. The characteristics of 1,865 participants (858 men, 1,007 women) are shown in Table 1. Routine blood examinations that included total serum cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, and glucose levels were performed. A physician or nurse interviewed each patient in regard to smoking and drinking habits and personal history of cardiovascular disease, including angina pectoris, myocardial infarction, and/or stroke.

Blood pressure was measured in a sitting position after at least 10 min of rest. Systolic and diastolic blood pressures (SBP/DBP) were taken as the means of two measurements recorded more than 3 min apart by well-trained doctors. Hypertension was defined as SBP of ≥140 mmHg, DBP of ≥90 mmHg, or the current use of antihypertensive medication (18). Diabetes mellitus was defined as fasting plasma glucose ≥7.0 mmol/l (126 mg/dl), non-fasting plasma glucose ≥11.1 mmol/l (200 mg/dl), current use of antidiabetic medication, or HbA1c ≥6.5%. Hyperlipidemia was defined as total cholesterol ≥5.68 mmol/l (220 mg/dl) or current use of antihyperlipidemia medication. Body mass index (BMI)



**Fig. 1.** Genome structure of human *NCX1*. The *NCX1* gene consists of sixteen exons, five (exons 1a–1e) of which direct tissue-specific transcription and eleven (exons 2–12) of which encode the open reading frame (17). The five tissue-specific transcription exons (exons 1a–1e) and the exons in which the SNPs were identified are depicted. The nucleotide changes and amino acid substitutions are also shown. The A of the ATG of the initiator Met codon is denoted nucleotide +1.

was calculated as weight (in kg) divided by height (in m) squared.

#### Direct Sequencing for Single Nucleotide Polymorphism (SNP) Discovery and Genotyping of Polymorphisms

For DNA sequencing, 96 patients with essential hypertension were recruited from the Division of Hypertension and Nephrology, National Cardiovascular Center, Japan. The method of direct sequencing was described previously (19). Fifteen polymorphisms were identified by sequencing and 7 representative polymorphisms with a minor allele frequency of greater than 4% were genotyped by the TaqMan-polymerase chain reaction (PCR) system (20). Only those who gave written informed consent for genetic analyses were included in this study. The study protocol was approved by the Ethical Review Committee of the National Cardiovascular Center.

#### Statistical Analysis

Analysis of variance was used to compare mean values between groups, and if overall significance was demonstrated, the intergroup difference was assessed by means of a general linear model. Frequencies were compared by  $\chi^2$  analysis.

Logistic regression analyses were used to examine the association between the genotypes and blood pressure in each sex with consideration for potential confounding risk variables, including age, BMI, present illness (hyperlipidemia and diabetes mellitus), lifestyle (smoking and drinking), and antihypertensive medication. For multivariate risk predictors, the adjusted odds ratios were given with 95% confidence intervals. The relationship between genotype and risk of hypertension was expressed in terms of the odds ratios adjusted for possible confounding effects including age, BMI, present illness (hyperlipidemia and diabetes mellitus), and lifestyle (smoking and drinking). SAS statistical software (release

8.2; SAS Institute, Cary, USA) was used for statistical analyses (21).

## Results

#### Basic Characteristics of Subjects in the Suita Study

The characteristics of the 1,865 participants (858 men, 1,007 women) are summarized in Table 1. Age, SBP, DBP, BMI, percentage of current smokers, percentage of current drinkers, and prevalence of hypertension and diabetes mellitus were significantly higher in men than in women. Total cholesterol, HDL-cholesterol, and percentage of hyperlipidemia were significantly higher in women than in men.

#### Polymorphisms of *NCX1*

The *NCX1* gene has a complicated genome structure containing five alternative 5' exons producing separate tissue-specific promoters and six exons encoding open reading frames (Fig. 1). We sequenced the entire exon and promoter regions of *NCX1* from 96 patients (182 alleles) with hypertension, and identified 15 polymorphisms (Table 2, Fig. 1). We identified two missense mutations, Arg5Gln in exon 2 and Arg703Cys in exon 9, in *NCX1* (Table 2). Each of the missense mutations was identified in one out of 96 individuals, indicating that their allele frequencies were rare. Two SNPs, -23200T>C and -23186G>C, were in linkage disequilibrium. Seven representative polymorphisms with a minor allele frequency of greater than 4% were genotyped for the association study.

#### Susceptible SNPs Related to Hypertension

Seven polymorphisms in *NCX1* were genotyped in 1,865 individuals, of whom 787 were hypertensive and 1,072 were normotensive. The primers and probes of the TagMan-PCR system and the genotyping results are summarized in Table

**Table 2. List of 15 Polymorphisms and Their Allele Frequencies in the *NCX1* Gene Identified by Direct Sequencing**

Allele 1/Allele 2 SNPs	TaqMan typing	Amino acid change	Region	Allele 1 Homo	Hetero	Allele 2 Homo	Total	Allele frequency		Flanking sequence
								Allele 1	Allele 2	
-23846A>C			intron 1d	94	1	0	95	0.995	0.005	tcacactgcctt[a/c]aattcaggagct
-23690T>C	typing		intron 1d	62	31	2	95	0.816	0.184	aaatttaactta[t/c]agcaaggaaga
-23449C>A	typing		intron 1d	85	9	1	95	0.942	0.058	catactcacatt[c/a]atgtttgaggag
-23200T>C*	typing		intron 1d	0	9	86	95	0.047	0.953	attccgccccct[t/c]ttgttcggag
-23186G>C*			intron 1d	0	9	86	95	0.047	0.953	ttgttcggagg[g/c]aaactgaggtc
-23181T>C	typing		intron 1d	18	57	20	95	0.489	0.511	gcggaggcaaac[t/c]gaggttcctgga
-22729A>C	typing		intron 1c	71	23	1	95	0.868	0.132	taattatgagga[a/c]agtgattattg
-22660delA			intron 1c	94	1	0	95	0.995	0.005	gattgctgcat[a/-]ggtttttccca
-22387A>C		5' UTR	exon 1b	93	3	0	96	0.984	0.016	attaaaaaaaa[a/c]tcattgatata
-22144C>G	typing		intron 1b	84	9	2	95	0.932	0.068	gcgcgccacaa[c/g]gcactgcggggc
14G>A		Arg5Gln	exon 2	95	1	0	96	0.995	0.005	tgtacaacatgc[g/a]gcgattaagtct
303C>T		Ser101Ser	exon 2	95	1	0	96	0.995	0.005	tcggttcgatgc[c/t]tctatagaagtc
252581G>A	typing		intron 4	45	40	11	96	0.677	0.323	tcttctctcc[g/a]tctcctact
255089-255090insA			intron 5	94	1	0	95	0.995	0.005	tcaggatgataca[-/a]gtagctctgtga
265364C>T		Arg703Cys	exon 9	95	1	0	96	0.995	0.005	gcagaaatgggg[c/t]ccccatcctgg

The A of the ATG of the initiator Met codon is denoted nucleotide +1. \*The apparent linkage disequilibrium ( $r^2 \geq 0.5$ ). *NCX1*, Na<sup>+</sup>/Ca<sup>2+</sup> exchanger; SNP, single nucleotide polymorphism.

3. Multivariate logistic regression analysis after adjusting for confounding risk variables such as age, BMI, hyperlipidemia, diabetes mellitus, smoking, and drinking, revealed that two polymorphisms, -23200T>C and -23181T>C, in the 5' upstream region of exon 1c were significantly associated with hypertension in men (-23200T>C: CC vs. TC+TT: odds ratio=0.61; 95% confidence interval: 0.39 to 0.97;  $p=0.04$ ) and in women (-23181T>C: CC vs. TC+TT: odds ratio=1.45; 95% confidence interval: 1.04 to 2.02;  $p=0.03$ ), respectively (Table 4). When normotension was defined as SBP  $\leq 120$  mmHg, DBP  $\leq 80$  mmHg, and the absence of anti-hypertensive medication, and hypertension was defined as SBP  $\geq 160$  mmHg, DBP  $\geq 100$  mmHg, or the current use of antihypertensive medication, -23200T>C polymorphism was significantly associated with hypertension in men (CC vs. TC+TT: odds ratio=0.42; 95% confidence interval: 0.20 to 0.92;  $p=0.03$ ) after adjusting for the confounding factors described above.

## Discussion

In this study, we sequenced the exon and promoter regions of *NCX1* and identified 15 polymorphisms. Seven representative polymorphisms were genotyped from 1,865 subjects to examine the association of hypertension with *NCX1*. After adjustment for various confounding factors, we identified that the -23200T>C polymorphism in the 5' upstream region of exon 1c was significantly associated with hypertension in men and the -23181T>C polymorphism in the 5' upstream region of exon 1c was significantly associated with hypertension in women.

The *NCX1* gene has at least 12 splice variants generated in different combinations from six exons in a tissue-specific manner (13). In addition, three exons encode 5'-untranslated sequences that are under the control of three tissue-specific promoters (14-16). Exon 1c is a part of the "heart" specific transcript (17) and its upstream region is not likely a promoter. Therefore, the -23200T>C and -23181T>C polymorphisms present in the upstream region of exon 1c are not likely to be directly involved in transcription of *NCX1*. Rather, these polymorphisms may be in linkage disequilibrium with other polymorphisms in the region that were not examined by sequencing in this study.

In this study, the -23200T>C polymorphism in men and -23181T>C polymorphism in women were identified as SNPs conferring susceptibility for hypertension. It is well known that the greater incidence of hypertension and coronary artery disease in men is, in part, related to gender differences in possible vascular protective effects of the female sex hormones estrogen and progesterone. Furthermore, *NCX1* might be related to salt-sensitive hypertension (22). Since there is a gender difference in salt-sensitivity and plasma renin activity (23, 24), -23200T>C and -23181T>C in *NCX1* may be linked with unidentified causative genetic variations that would be influenced by the female sex hormones and/or salt-sensitivity.

In this study, we identified two missense mutations, Arg5Gln in exon 2 and Arg703Cys in exon 9, in *NCX1*. Arg5 is located within the signal peptide sequence consisting of the first N-terminal 35 amino acids of *NCX1*, which are removed during biosynthesis (1). We expressed a mutant canine *NCX1* with the Arg5Gln substitution in the fibroblastic

Table 3. Genotyping Conditions and Results of NCX1 Polymorphisms in 1,818 Individuals by TaqMan-PCR Method

SNP	Primer	Probe	Genotypes results
-23690T>C	CTCTCCCCACAGGTCATTCTG	Fam-ATTTAACTTATAGCAAGGAA-MGB	(TT/TC/CC)
	GCAGGAATCGTTCCTGCCTAA	Vic-TTAACTTACAGCAAGGAA-MGB	=(1,140/590/88)
-23449C>A	GAATCTGCAATCCCCATGTGAT	Fam-CTCACATTCATGTTTGAG-MGB	(CC/CA/AA)
	AGAACCACTGCTCTAGGCCAAT	Vic-ACTCACATTAATGTTTGAGG-MGB	=(1,542/261/15)
-23200T>C	TTCTGAGGTGCAAGGAGGGTT	Fam-CCCCCTTTTGTGTC-MGB	(TT/TC/CC)
	GGCAGTCACCACGACTGATAGA	Vic-CCCCCTTTTGTGTC-MGB	=(4/196/1,618)
-23181T>C	GGCAGTCACCACGACTGATAGA	Fam-TCCAGGAACCTCAGTTT-MGB	(TT/TC/CC)
	AGGCTATTTCTTCCATTCCGC	Vic-CCAGGAACCTCGGTTT-MGB	=(503/869/446)
-22729A>C	GCCTGGTGCAGTGTTCCCTTA	Fam-ATTATGAGGAAAGTGATTTA-MGB	(AA/AC/CC)
	GCCCTTTCCAAGAGAAGCATT	Vic-TATGAGGACAGTGATTTA-MGB	=(1,369/406/43)
-22144C>G	AAAAGAAAAGTTGCAGCGCCT	Fam-CCACAACGCACTGC-MGB	(CC/CG/GG)
	TTTTTCGATTTCCCTGCCGG	Vic-CACAAGGCACTGCG-MGB	=(1,687/131/0)
252581G>A	AAACAAAGACATACCAGCGAGAAA	Fam-CTCTCTCCGTGTCTC-MGB	(GG/GA/AA)
	AAATTGCTAAAGCTTCAAAGGCA	Vic-TCTCTCCATGTCTCC-MGB	=(823/798/197)

PCR, polymerase chain reaction; SNP, single nucleotide polymorphism.

Table 4. Odds Ratio of -23200T&gt;C Polymorphism in Men and -23181T&gt;C Polymorphism in Women\*

Gender	SNP	OR (95% CI)	p	OR (95% CI)	p
Men	-23200T>C	CC	1 (reference)	CC+TC	1 (reference)
		TC+TT	0.61 (0.39-0.97)	TT	—
Women	-23181T>C	CC	1 (reference)	CC+TC	1 (reference)
		TC+TT	1.45 (1.04-2.02)	TT	1.39 (1.00-1.92)

\*Conditional logistic analysis, adjusted for age, body mass index, present illness (hyperlipidemia and diabetes mellitus), and lifestyle (smoking and drinking). SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence intervals.

cell line CCL39, and found that this mutant NCX1 was properly targeted into the plasma membrane and exhibited the normal Na<sup>+</sup>/Ca<sup>2+</sup> exchange activity (unpublished observations), consistent with previous reports stating that signal sequence is not essential for functional expression of the NCX1 protein (25, 26). On the other hand, Arg703 is located within the large cytoplasmic loop connecting the transmembrane segments 5 and 6, which are not essential for the functional expression of the NCX1 protein (1). Thus, the two rare mutations identified in this study would not grossly impair the function of NCX1.

In summary, we showed that the SNPs -23200T>C and -23181T>C in NCX1 were associated with hypertension. The pathophysiological functional behaviors of these polymorphisms remain to be clarified. In future studies, it will be necessary to clarify the function of these polymorphisms or to identify the causative polymorphisms that are in linkage disequilibrium with these polymorphisms.

### Acknowledgements

We would like to express our highest gratitude to Dr. Soichiro Kitamura, President of the National Cardiovascular Center, for

his support of the Millennium genome project (MPJ-3). We would also like to thank Dr. Katsuyuki Kawanishi, Dr. Toshifumi Mannami, and Mr. Tadashi Fujikawa for their continuous support of our population survey in Suita City. We also thank the members of the Satsuki-Junyukai. We also thank all the staff in the Division of Preventive Cardiology for supporting medical examination and M. Banno, Y. Tokunaga, and C. Imai for their technical assistance. Finally, we are grateful to Dr. Tetsuji Yokoyama for his statistical advice.

### References

- Philipson KD, Nicoll DA: Sodium-calcium exchange: a molecular perspective. *Annu Rev Physiol* 2000; 62: 111-133.
- Shigekawa M, Iwamoto T: Cardiac Na<sup>+</sup>-Ca<sup>2+</sup> exchange: molecular and pharmacological aspects. *Circ Res* 2001; 88: 864-876.
- Blaustein MP, Lederer WJ: Sodium/calcium exchange: its physiological implications. *Physiol Rev* 1999; 79: 763-854.
- Blaustein MP: Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. *Am J Physiol* 1977; 232: C165-C173.
- Blaustein MP: Physiological effects of endogenous ouabain: control of intracellular Ca<sup>2+</sup> stores and cell respon-